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Getting the needle
The incidence of HIV/AIDS in infants and children in sub-
Saharan Africa has spawned an important debate. On the one
hand Gisselquist and collaborators make a case for the
horizontal spread of HIV/AIDS to be much higher than
generally believed, claiming that much of this is due to medical
intervention, especially the use of contaminated injections and
infusions (see last month’s SAMJ). Their views have been
challenged in a thoughtful analysis published by Schmid et al.
(Lancet 2004; 363: 482-488). Two articles in this SAMJ add useful
information to this debate. 
Unexplained HIV-1 infection in children is the subject of a
comprehensive analysis by Hiemstra et al. (p. 188). Following
earlier reports of possible horizontal transmission of HIV-1
infection between siblings, a registry was established at
Tygerberg Children’s Hospital for further collection of data.
Fourteen children with unexplained HIV infection were
identified and investigated.
Children acquire HIV-1 infection through vertical
transmission occurring in utero, during the birth process, or
postnatally through breast-feeding. Other recognised routes
include contaminated blood products and sexual abuse. In this
series intravenous cannulation and intravenous drug
administration occurred in all but 2 children before HIV
diagnosis. The authors conclude that circumstantial evidence
supports but does not prove nosocomial infection. 
The other contribution is by Daly, Nxumalo and Bielik 
(p. 194), who investigated injection practices in Swaziland.
Previous studies have found that unsafe injection practices are
widespread in West and East Africa and the safety of injection
practices in vaccination programmes continues to constitute a
worldwide concern. In Swaziland, each child receives 8
injections to complete the routine vaccination schedule during
the first year of life and many clients seeking curative services
favour injectables over other forms of treatment. Since unsafe
injection practices occur even in settings where health care
workers have been properly trained, the possible transmission of
blood-borne pathogens such as HIV and hepatitis B continues
to be a concern. Daly et al. found that clients are exposed to
unacceptable risks from re-use of syringes and needles.
Conclusions that may be drawn from all these contributions
are that there is an urgent need to re-evaluate and improve
infection control practices in health care settings, and that there
is no longer any justification not to switch to using auto-
disposable syringes for all routine and supplemental
vaccinations. Of great concern are the limited frequency,
quality and impact of supervision.
Smoking fires new rounds
Yussuf Saloojee fires a critical round at Chris Bateman’s ‘No
smoke without fire’ report in the January SAMJ, though his
response (p. 164) is even more damning of the tobacco
industry. Chris in turn brings us up to date on developments
concerning the anti-tobacco legislation (p. 150).
While readers may not have interpreted the first Bateman
salvo in the negative way that Saloojee has, all this material
serves several purposes. The first is that excellent investigative
reporting has uncovered several flaws in the proposed
legislation. Secondly it has reinforced the importance of
responsible responses by the public. Thirdly South Africa’s
tendency to become what the media has labelled ‘a nanny
society’ is too apparent with the increasing central control
through the welter of new laws.
Bones strengthened
The National Osteoporosis Foundation of South Africa has
done the profession a favour by producing a ‘position paper’
on the use of parathyroid hormone (PTH (1-34)) in the
treatment of osteoporosis (p. 175). 
The mainstay of current therapies for osteoporosis is
antiresorptive agents such as calcium, vitamin D, oestrogen,
selective oestrogen modulators, calcitonin and the
bisphosphonates. These drugs reduce but do not eliminate
fracture risk and do not restore lost bone structure. Anabolic
agents have the potential to increase bone mineral density,
restore skeletal micro-architecture and reduce fracture risk to a
greater extent than the antiresorptives. Recombinant human
PTH has emerged as the most promising osteo-anabolic agent
to date.
Administration of PTH causes rapid stimulation of bone
formation resulting in a marked increase in bone mass, size
and strength, as well as improvements in trabecular micro-
architecture. Daily subcutaneous injections of PTH (1-34) for as
little as 21 months reduced the risk of new vertebral fractures
by 65 - 70% and non-vertebral fractures by 35 - 40%. Side-
effects have been minimal and it is reasonable to conclude that
PTH is safe in human subjects.
With all these wonderful results what is the catch? PTH (1-
34) or teriparatide will soon become available as a treatment
option for osteoporosis in South Africa, and the usual serious
ethical dilemma with regard to the allocation of expensive
resources will be posed because of the high estimated cost 
(R50 000 per annum). 
The Osteoporosis Foundation recommends that PTH (1-34)
should only be used in patients with severe established
osteoporosis and provides further criteria for its use and
contraindications. Furthermore, each application for treatment
will be assessed by a working group consisting of senior
council members of the National Osteoporosis Foundation of
South Africa.
Osteoporosis is such a common condition that readers will
be intrigued to know if the potential large numbers of
applicants will not swamp the proposed mechanism. And what
will happen if patients with the means and desire wish to
obtain treatment outside of this cosy arrangement? 
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